- Home
- CVKD vs INAB Comparison
CVKD vs INAB Comparison
Compare CVKD & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVKD | INAB |
|---|---|---|
| Founded | 2022 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7M | 22.9M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CVKD | INAB |
|---|---|---|
| Price | $7.32 | $2.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $32.00 | ★ $108.00 |
| AVG Volume (30 Days) | 51.9K | ★ 177.8K |
| Earning Date | 03-12-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.42 | $1.17 |
| 52 Week High | $22.90 | $12.53 |
Technical Indicators
Market Signals| Indicator | CVKD | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 42.21 | 57.65 |
| Support Level | $6.85 | $2.30 |
| Resistance Level | $7.87 | $2.73 |
| Average True Range (ATR) | 0.59 | 0.25 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 33.64 | 50.79 |
Price Performance
Historical ComparisonAbout CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.